Clinical trial
A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis…
NCT00207688 · Janssen Research & Development, LLC, Industry · Completed
Key facts
| NCT number | NCT00207688 |
|---|---|
| Title | A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients |
| Official title | A Multicenter International Study of the Long-term Safety of Infliximab (REMICADE) in Ulcerative Colitis |
| Lead sponsor | Janssen Research & Development, LLC, Industry |
| Collaborators | Janssen Biologics BV |
| Status | Completed |
| Study type | Observational |
| Conditions | Ulcerative Colitis |
| Intervention type | Drug |
| Interventions | Infliximab 5 mg/kg, Infliximab 10 mg/kg, Placebo |
| Enrollment | 505 |
| Start date | Aug 31, 2004 |
| Primary completion | Sep 9, 2015 |
| Completion | Sep 9, 2015 |
| First posted | Sep 21, 2005 |
| Last update posted | Jul 6, 2018 |
| Countries | Argentina, Australia, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Israel, Netherlands, New Zealand and 3 more |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: